Actavis Sued by New York A.G. Over Alzheimer’s Drug Swap
This article is for subscribers only.
Actavis Plc was sued by New York Attorney General Eric Schneiderman over claims it’s trying to block generic competition by swapping versions of its Namenda Alzheimer’s drug, a move he says is part of a growing trend in the pharmaceutical industry to maintain high prices.
The Dublin-based company’s plan to discontinue the immediate-release version of its Namenda Alzheimer’s drug and switch patients to an extended-release version with patents expiring later violates state and U.S. antitrust laws, Schneiderman said in complaint filed yesterday in Manhattan federal court.